BRAFV600E status and clinical characteristics in solitary and multiple papillary thyroid carcinoma: experience of 512 cases at a clinical center in China

被引:17
|
作者
Zheng, Xiangqian [1 ]
Xia, Tingting [1 ]
Lin, Lin [1 ]
Gao, Songyuan [3 ]
Lee, Yigong [1 ]
Yu, Yang [1 ]
Wei, Songfeng [1 ]
Gao, Ming [1 ,2 ]
机构
[1] Tianjin Med Univ, Canc Inst & Hosp, Oncol Key Lab Canc Prevent & Therapy, Tianjin, Peoples R China
[2] Tianjin Med Univ, Canc Hosp & Inst, Dept Thyroid & Neck Tumor, Tianjin 300060, Peoples R China
[3] Tsinghua Univ, Dept Pathol, Tsinghua Univ Med Coll, Beijing 100084, Peoples R China
来源
WORLD JOURNAL OF SURGICAL ONCOLOGY | 2012年 / 10卷
关键词
Papillary thyroid carcinoma; Multiple PTC; Solitary PTC; BRAF(V600E) mutation; BRAF MUTATIONS; INTRAGLANDULAR DISSEMINATION; CANCER; MICROCARCINOMA; PREVALENCE; GENE; METAANALYSIS; INVOLVEMENT; METASTASIS; FEATURES;
D O I
10.1186/1477-7819-10-104
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Papillary thyroid carcinoma (PTC) is one of the most frequent endocrine malignancies. In most cases, it often presents as multifocal tumor. It has been reported that multifocal tumors are associated with elevated risk of lymph node and distant metastases. Multifocality is also one of the factors predicting prognosis. Recent studies show that BRAF(V600E) mutation occurs more frequently in aggressive PTC. The purpose of this study was to evaluate BRAF(V600E) status and clinicopathological features in multiple and solitary PTC. Methods: We performed a retrospective study to analyze 512 PTC cases who received surgery, including 376 solitary PTCs and 136 multiple PTCs. Results: Multiple PTC is more related to lymph node metastasis and vascular invasion than solitary PTC. However, the distant metastasis rate and 10-year survival rate showed no difference between these two groups. BRAF(V600E) mutation status was more frequent in multiple PTC patients with lymph node metastasis and late stage at diagnosis. Conclusion: BRAF(V600E) mutation is most commonly associated with extra-thyroidal extension and lymph node metastasis in PTC. Multiple PTC patients with young age, large tumors and BRAF(V600E) mutation should be followed carefully. Our study provides useful information for PTC patients' followup and treatment.
引用
收藏
页数:7
相关论文
共 50 条
  • [21] Meta-Analyses of Association Between BRAFV600E Mutation and Clinicopathological Features of Papillary Thyroid Carcinoma
    Zhang, Qing
    Liu, Shao-zheng
    Zhang, Qing
    Guan, Yan-xing
    Chen, Qing-jie
    Zhu, Qin-yao
    CELLULAR PHYSIOLOGY AND BIOCHEMISTRY, 2016, 38 (02) : 763 - 776
  • [22] Single BRAFV600E mutation is not associated with aggressive biological behavior in adolescent and pediatric papillary thyroid carcinoma
    Zhou, Bin
    Lu, Xiaoyu
    Hei, Hu
    Zhang, Songtao
    Li, Yanqing
    Fang, Jugao
    Qin, Jianwu
    Ge, Hong
    CANCER CYTOPATHOLOGY, 2023, 131 (11) : 716 - 723
  • [23] The Association of the BRAFV600E Mutation With Prognostic Factors and Poor Clinical Outcome in Papillary Thyroid Cancer
    Kim, Tae Hyuk
    Park, Young Joo
    Lim, Jung Ah
    Ahn, Hwa Young
    Lee, Eun Kyung
    Lee, You Jin
    Kim, Kyung Won
    Hahn, Seo Kyung
    Youn, Yeo Kyu
    Kim, Kwang Hyun
    Cho, Bo Youn
    Park, Do Joon
    CANCER, 2012, 118 (07) : 1764 - 1773
  • [24] The BRAFV600E mutation in papillary thyroid microcarcinoma: does the mutation have an impact on clinical outcome?
    Walczyk, Agnieszka
    Kowalska, Aldona
    Kowalik, Artur
    Sygut, Jacek
    Wypiorkiewicz, Elzbieta
    Chodurska, Renata
    Pieciak, Liliana
    Gozdz, Stanislaw
    CLINICAL ENDOCRINOLOGY, 2014, 80 (06) : 899 - 904
  • [25] The Primary Occurrence of BRAFV600E Is a Rare Clonal Event in Papillary Thyroid Carcinoma
    Guerra, Anna
    Sapio, Maria Rosaria
    Marotta, Vincenzo
    Campanile, Elisabetta
    Rossi, Stefania
    Forno, Irene
    Fugazzola, Laura
    Budillon, Alfredo
    Moccia, Tania
    Fenzi, Gianfranco
    Vitale, Mario
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2012, 97 (02) : 517 - 524
  • [26] Clinical and Sonographic Differences Between RET Fusion-positive and BRAFV600E in Papillary Thyroid Carcinoma
    Chen, Zixian
    Sun, Wenyu
    Fei, Mengjia
    Qian, Kai
    Shi, Yuan
    Guo, Kai
    Wang, Zhuoying
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2024,
  • [27] Pathologic Characteristics, Natural History, and Prognostic Implications of BRAFV600E Mutation in Pediatric Papillary Thyroid Carcinoma
    Hardee, Steven
    Prasad, Manju L.
    Hui, Pei
    Dinauer, Catherine A.
    Morotti, Raffaella A.
    PEDIATRIC AND DEVELOPMENTAL PATHOLOGY, 2017, 20 (03) : 206 - 212
  • [28] Risk and Prognostic Factors for BRAFV600E Mutations in Papillary Thyroid Carcinoma
    Wei, Xiaojing
    Wang, Xiaodong
    Xiong, Jie
    Li, Chen
    Liao, Yixuan
    Zhu, Yongjun
    Mao, Jingxin
    BIOMED RESEARCH INTERNATIONAL, 2022, 2022
  • [29] The Presence of Typical "BRAFV600E-Like" Atypia in Papillary Thyroid Carcinoma is Highly Specific for the Presence of the BRAFV600E Mutation
    Turchini, John
    Sioson, Loretta
    Clarkson, Adele
    Sheen, Amy
    Delbridge, Leigh
    Glover, Anthony
    Sywak, Mark
    Sidhu, Stan
    Gill, Anthony J.
    ENDOCRINE PATHOLOGY, 2023, 34 (01) : 112 - 118
  • [30] Noninferior response in BRAFV600E mutant nonmetastatic papillary thyroid carcinoma to radioiodine therapy
    Li, Jiao
    Liang, Jun
    Zhao, Teng
    Lin, Yansong
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2016, 43 (06) : 1034 - 1039